Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

Similar articles for PubMed (Select 18519753)

1.

Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.

Steffensen KD, Waldstrøm M, Olsen DA, Corydon T, Lorentzen KA, Knudsen HJ, Jeppesen U, Brandslund I, Jakobsen A.

Clin Cancer Res. 2008 Jun 1;14(11):3278-82. doi: 10.1158/1078-0432.CCR-07-4171.

2.
3.

Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III.

Zeineldin R, Rosenberg M, Ortega D, Buhr C, Chavez MG, Stack MS, Kusewitt DF, Hudson LG.

Mol Carcinog. 2006 Nov;45(11):851-60.

PMID:
16788982
4.

Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.

Yang B, Chen J, Zhang X, Cao J.

Auris Nasus Larynx. 2009 Dec;36(6):682-7. doi: 10.1016/j.anl.2009.03.002. Epub 2009 May 7.

PMID:
19427146
5.

Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M.

Clin Cancer Res. 2006 Aug 1;12(15):4671-7.

6.

Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.

Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.

Clin Cancer Res. 2004 Oct 1;10(19):6732-43.

7.

Lack of the type III epidermal growth factor receptor mutation in colorectal cancer.

Spindler KL, Olsen DA, Nielsen JN, Brandslund I, Poulsen HS, Villingshøj M, Jakobsen A.

Anticancer Res. 2006 Nov-Dec;26(6C):4889-93.

8.

Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.

Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.

Cancer Res. 2006 Jan 15;66(2):867-74.

9.

EGFRvIII mutation in lung cancer correlates with increased EGFR copy number.

Sasaki H, Kawano O, Endo K, Yukiue H, Yano M, Fujii Y.

Oncol Rep. 2007 Feb;17(2):319-23.

PMID:
17203167
10.

Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors.

Dimova I, Zaharieva B, Raitcheva S, Dimitrov R, Doganov N, Toncheva D.

Int J Gynecol Cancer. 2006 Jan-Feb;16(1):145-51.

PMID:
16445625
11.

Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas.

Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H.

Brain Pathol. 2004 Apr;14(2):131-6.

PMID:
15193025
12.

Pineal parenchymal tumor of intermediate differentiation: clinicopathological report and analysis of epidermal growth factor receptor variant III expression.

Li G, Mitra S, Karamchandani J, Edwards MS, Wong AJ.

Neurosurgery. 2010 May;66(5):963-8; discussion 968. doi: 10.1227/01.NEU.0000367726.49003.F1.

PMID:
20404701
13.

Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.

Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW.

Ann Surg Oncol. 2009 Jan;16(1):152-8. doi: 10.1245/s10434-008-0206-6. Epub 2008 Nov 8.

PMID:
18998063
14.

Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer.

Ilekis JV, Gariti J, Niederberger C, Scoccia B.

Gynecol Oncol. 1997 Apr;65(1):36-41.

PMID:
9103388
15.

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K.

Clin Cancer Res. 2005 Feb 15;11(4):1462-6.

16.

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.

Steffensen KD, Waldstrøm M, Andersen RF, Olsen DA, Jeppesen U, Knudsen HJ, Brandslund I, Jakobsen A.

Int J Oncol. 2008 Jul;33(1):195-204.

PMID:
18575766
17.

Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer.

Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W, Saigenji K, Danenberg PV, Lenz HJ.

Clin Colorectal Cancer. 2006 Sep;6(3):214-8.

PMID:
17026791
18.

Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.

Hama T, Yuza Y, Saito Y, O-uchi J, Kondo S, Okabe M, Yamada H, Kato T, Moriyama H, Kurihara S, Urashima M.

Oncologist. 2009 Sep;14(9):900-8. doi: 10.1634/theoncologist.2009-0058. Epub 2009 Sep 2. Erratum in: Oncologist. 2009 Oct;14(10):1050.

19.

Targeting EGFR in bladder cancer.

Villares GJ, Zigler M, Blehm K, Bogdan C, McConkey D, Colin D, Bar-Eli M.

World J Urol. 2007 Dec;25(6):573-9. Epub 2007 Aug 10. Retraction in: World J Urol. 2012 Oct;30(5):723.

PMID:
17690890
20.

The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment.

Theys J, Jutten B, Dubois L, Rouschop KM, Chiu RK, Li Y, Paesmans K, Lambin P, Lammering G, Wouters BG.

Radiother Oncol. 2009 Sep;92(3):399-404. doi: 10.1016/j.radonc.2009.06.017. Epub 2009 Jul 16.

PMID:
19616331
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk